Webinar:

Pre-ASCO 2018 ā€“ Major Cancer Catalysts at the Conference

Sponsored by: GlobalData

Focused on:

  • Asco
  • Oncology Conference

Date: 25 May

Days to go: 5

Time: 3PM London/10AM New York

This expert presentation is exclusive only for GlobalData's clients. The recording and presentation will be available on the Intelligence Center. For any requests or questions please contact marketing@globaldata.com

Oncologists around the globe are again heading to Chicago this June for the American Society of Clinical Oncology (ASCO) conference, taking place 1-5 June. This is the biggest cancer conference of the year at around 40, 000 attendees with the majority being medical and healthcare professionals and industry representatives.

During the adrenaline-packed five days, attendees will be speaking, presenting, learning and networking, while reporters from GlobalData's investigative news team will be on the ground meeting sources. They will also be getting reactions to the conference's most catalytic events and tapping into ASCO's undercurrents that are not at the forefront of the conference.

In this expert presentation, GlobalData's reporters will take attendees through abstracts expected to have the biggest impact during the conference.

Our cancer reporters have already published forward-looking articles on the major events expected at ASCO. They've been speaking to KOLs, investigators, biostatisticians and other cancer experts on the potential for the most anticipated readouts. This year, the industry will again be closely following data presented by major immuno-oncology (IO) players such as Bristol-Myers Squibb, Merck, Roche, AstraZeneca and Pfizer to better ascertain the competitive and rapidly evolving IO landscape. Moreover, catalytic data from mid-size firms such as Loxo Oncology, bluebird bio, Tesaro, ImmunoGen, Adaptimmune Therapeutics and others will provide a better look into efficacy, safety and durability of treatments. Readouts from smaller companies such as Jounce Therapeutics, Syndax Pharmaceuticals, Idera Pharmaceuticals, Ignyta, MacroGenics and NewLink Genetics among others will also be under the spotlight.

The team's coverage ahead of ASCO spans an array of indications including melanoma;lung, ovarian, breast, pancreatic, gastric and colorectal cancers;NTRK fusions in solid tumorsand liquid tumors including multiple myeloma and acute myeloid leukemia.

Our journalists have spoken to experts ahead of ASCO's potentially market moving readouts-- ranging from Phase I to Phase III -- to obtain fact-based commentary on chances for success. Experts have also commented on various drugs'safety and tolerability risks, their potential to move through the development pipeline and accelerated pathways as well as their market outlook.

GlobalData'sreporters Reynald Castaneda and Manasi Vaidya will discuss what they have reported -- based on KOL interviews-- in the months leading up to the big event. North America editor Surani Fernando will moderate the presentation, followed by a Q&A session.

Presented by

Manasi Vaidya,

Reporter, North America

Since joining the New York team in February 2015, Manasi was one of news team's dedicated oncology reporters. Manasi now covers both non-cancer and cancer beats, of which breast, lung, ovarian, urothelial and kidney cancer fall under her coverage areas. She has covered high profile conferences like ASCO and SABC, in addition to FDA regulatory meetings. Manasi previously covered the Asian biotechnology industry for BioSpectrum, a monthly magazine in India, for two years. She has a Masters degree in Science, Health and Environmental Reporting from New York University, and a Masters degree in Biotechnology from Dr. D. Y. Patil University. Her work has appeared in Nature Medicine, Nautilus and Technology Review India.

Reynald Castaneda,

Reporter, EMEA

Reynald Castaneda joined in August 2015 covering an extensive list of therapeutic areas, including dermatology and liver diseases, and in 2016 expanded his coverage to melanoma, liver, gastric, colon and pancreatic cancers in 2016. Prior to moving to London, Reynald was a journalist for primary care newspaper New Zealand Doctor covering health politics and medical research. He has a BSc in Biological Sciences from the University of Auckland and a postgraduate diploma in journalism from AUT University. Before becoming a journalist, Reynald worked as a laboratory technician for Massey University's Institute of Molecular Biosciences.

Surani Fernando,

Editor, North America

Surani Fernando manages the North America editorial desk. Since joining the London newsroom in 2010, Surani has generated a number of market-moving scoops and in-depth analyses on the drug development sector. Surani has covered academic and industry meetings in Europe and the US and has made TV appearances on CNBC and Sky News. Prior to journalism she worked in clinical operations at CRO PAREXEL. She has a Bachelor of Medical Science and Master of Health Communication, both from Sydney University, Australia

Key Learning Objectives

  • Which companies, diseases and drugs are getting the most attention
  • Efficacy benchmarks for success in specific trial designs
  • Combination potential and safety consequences
  • Treatment paradigm and market uptake outlook

Audience

  • Managers/Senior Managers/Associate
  • Directors/Directors of Market Research
  • Business Insights
  • Market Intelligence
  • Strategic Insights
  • Forecasting
  • Pipeline Management
  • Competitive Strategy
  • Customer Insights
  • Heads of Research and Development
  • Heads of Product Planning and Marketing
  • Brand Managers
  • Safety/Regulatory/Pharmacovigilence
  • Investment Manager
  • Investment Analyst
  • Healthcare Managing Director
  • Director of Research
  • Research / Coverage Analyst In CRO/CMO space: Business Development Feasibility
  • Head of R&D
  • Regulatory In agencies: Chief Strategy Officer
  • SVP / EVP Strategic Planning
  • VP Business Development
  • Managing Director
  • Principal